Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S0140-6736(19)31662-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Chronic kidney disease.
Nat Rev Dis Primers
January 2025
Division of Nephrology, Department of Medicine IV, Hospital of the Ludwig-Maximilians University, Munich, Germany.
Chronic kidney disease (CKD) is defined by persistent abnormalities of kidney function or structure that have consequences for the health. A progressive decline of excretory kidney function has effects on body homeostasis. CKD is tightly associated with accelerated cardiovascular disease and severe infections, and with premature death.
View Article and Find Full Text PDFLong-Term Stabilized and Highly Soluble Bezafibrate-Gliclazide Co-Amorphous Binary System.
AAPS PharmSciTech
January 2025
School of Engineering and Sciences, Tecnologico de Monterrey, Campus Monterrey, Ave. Eugenio Garza Sada 2501 Sur, C.P. 64849, Monterrey, N.L., Mexico.
Metabolic syndrome (MS) has a high prevalence, with an estimated one-quarter of the world population affected by this pathological condition. Among the diseases of this syndrome are dysregulation of lipids, hypertension, and insulin resistance. Unfortunately, available drugs in the market used for treating MS, as almost 75% of all drugs, are highly insoluble, presenting a significant demand for strategies to increase their solubility.
View Article and Find Full Text PDFDapagliflozin treatment decreases visceral and subcutaneous adipose tissue: a systematic review and meta-analysis.
Diabetol Int
January 2025
Facultad de Medicina, Benemérita Universidad Autónoma de Puebla, 13 Sur 2901 Colonia Volcanes, 72420 Puebla, Puebla México.
Aims: Sodium-glucose co-transporter-2 inhibitors (SGLT2i) have been shown to reduce visceral (VAT) and subcutaneous (SAT) adipose tissue. Although many systematic reviews have examined SGLT2i's effect on VAT and SAT, a focus analysis of dapagliflozin, one of the more commonly prescribe SGLT2i, has yet to been done. This study aims to determine the effect of dapagliflozin on reducing VAT and SAT in patients with chronic disease.
View Article and Find Full Text PDFA better diet quality based on the Healthy Eating Index-2020 is associated with lower energy intake and age but not with a pre-diabetes/T2DM diagnosis among Hispanic women with overweight/obesity.
Nutr Res
January 2025
College of Health Solutions, Arizona State University, Phoenix, AZ, USA; Southwest Interdisciplinary Research Center, Arizona State University, Phoenix, AZ, USA. Electronic address:
Low diet quality is related to obesity and type 2 diabetes mellitus (T2DM) risk among Hispanic women. This cross-sectional study compared diet quality among Hispanic women with overweight/obesity based on their T2DM diagnosis (pre-diabetes/T2DM group, n = 104 vs no diagnosis, at-risk group, n = 84). It was hypothesized that having a pre-diabetes or T2DM diagnosis would be associated with better diet quality based on the Healthy Eating Index (HEI)-2020 score.
View Article and Find Full Text PDFA Comprehensive Review of the Role of GLP-1 Agonists in Weight Management and Their Effect on Metabolic Parameters Such as Blood Glucose, Cholesterol, and Blood Pressure.
Cureus
December 2024
Internal Medicine, Combined Military Hospital, Quetta, PAK.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been developed to manage type 2 diabetes mellitus. Although, in the last 10 years, the use of GLP-1 RAs, especially semaglutide and liraglutide, has increased, its clinical implications and how it affects metabolic parameters have yet to be fully consolidated. This narrative review explores the metabolic effects of GLP-1 RAs in weight management, blood glucose, cardiovascular health, lipid profiles, and blood pressure.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!